Cara Therapeutics reported $-30001000 in Operating Profit for its second fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Acadia Pharmaceuticals ACAD:US $ -45M 45M
Aerie Pharmaceuticals AERI:US $ -43M 1M
Antares Pharma ATRS:US $ 3M 5M
Biodelivery Sciences International BDSI:US $ 2.94M 3.05M
Chugai Pharma 4519:JP Y 86690M 18472M
Depomed DEPO:US $ -4.81M 37.05M
Endo International Ordinary Shares ENDP:US $ 61.77M 81.85M
Halozyme Therapeutics HALO:US $ 29.56M 32.78M
Horizon Pharma HZNP:US $ 213.98M 193.37M
JAZZ PHA JAZZ:US $ 195.61M 1.98M
Johnson & Johnson JNJ:US $ 4401M 461M
Neurocrine Biosciences NBIX:US $ 76M 18M
Pacira Pharmaceuticals PCRX:US $ -7.15M 24.24M
Pfizer PFE:US $ 3441M 1147M
Redhill Biopharma RDHL:US $ -14.46M 1.96M
Revance Therapeutics RVNC:US $ -57105000 3.86M
Teva Pharmaceutical Industries TEVA:US $ -4342M 4515M
Vanda Pharmaceuticals VNDA:US $ 9.17M 9.3M